Clinical Trial

A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate safety and reactogenicity of the investigational pneumococcal vaccine (called Pn-MAPS30plus). PCV20 will be used as a comparator for this study
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-04-03 -> 2028-10-18 2026-07-17
minor Completion pushed: 2028-04-03 -> 2028-10-18 2026-07-17
Trial Details
NCT Number NCT07406347
Lead Sponsor GlaxoSmithKline
Conditions Pneumonia, Bacterial
Enrollment 60 participants
Start Date 2027-01-25
Primary Completion 2028-10-18 (estimated)
Study Completion 2028-10-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-16